305 related articles for article (PubMed ID: 19752342)
1. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
Liu MC; Shields PG; Warren RD; Cohen P; Wilkinson M; Ottaviano YL; Rao SB; Eng-Wong J; Seillier-Moiseiwitsch F; Noone AM; Isaacs C
J Clin Oncol; 2009 Nov; 27(31):5153-9. PubMed ID: 19752342
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
5. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
[TBL] [Abstract][Full Text] [Related]
6. HER2-targeted therapy influences CTC status in metastatic breast cancer.
Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
[TBL] [Abstract][Full Text] [Related]
7. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
8. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
11. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676
[TBL] [Abstract][Full Text] [Related]
12. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
Magbanua MJM; Hendrix LH; Hyslop T; Barry WT; Winer EP; Hudis C; Toppmeyer D; Carey LA; Partridge AH; Pierga JY; Fehm T; Vidal-Martínez J; Mavroudis D; Garcia-Saenz JA; Stebbing J; Gazzaniga P; Manso L; Zamarchi R; Antelo ML; Mattos-Arruda L; Generali D; Caldas C; Munzone E; Dirix L; Delson AL; Burstein HJ; Qadir M; Ma C; Scott JH; Bidard FC; Park JW; Rugo HS
J Natl Cancer Inst; 2021 Apr; 113(4):443-452. PubMed ID: 32770247
[TBL] [Abstract][Full Text] [Related]
13. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
15. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
Hayes DF; Cristofanilli M; Budd GT; Ellis MJ; Stopeck A; Miller MC; Matera J; Allard WJ; Doyle GV; Terstappen LW
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4218-24. PubMed ID: 16857794
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.
Martín M; Custodio S; de Las Casas ML; García-Sáenz JÁ; de la Torre JC; Bellón-Cano JM; López-Tarruella S; Vidaurreta-Lazaro M; de la Orden V; Jerez Y; Márquez-Rodas I; Casado A; Sastre J; Díaz-Rubio E
Oncologist; 2013; 18(8):917-23. PubMed ID: 23873719
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
[TBL] [Abstract][Full Text] [Related]
20. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]